A systematic strategy for producing biologically active full-length human peroxisome proliferator-activated receptor-(PPAR-) was developed. PPAR-was expressed as inclusion bodies in Terrific Broth (TB) ensuring stable pH, better growth conditions, and 4-fold higher cell yield as compared to Luria Broth (LB). Purification was performed by a combination of immobilized metal-ion affinity chromatography (IMAC) and size exclusion chromatography (SEC), yielding 176 mg of PPAR-of over 90% purity per liter of TB. A simplified refolding setup, capable of gradual buffer exchange and continuous protein feeding, was used to refold the denatured PPAR-with approximately 66% yield. Correct refolding of the denatured PPAR-was assessed with non-denaturing gels and SEC. The refolded PPAR-displayed its ligand binding ability for rosiglitazone at K d ¼ 250 AE 6 nM as determinated by SEC-HPLC assay. In addition, DNA binding activity of the refolded PPAR-was demonstrated by electrophoretic mobility shift assay (EMSA) using a PPRE motif. The integrity of PPAR-was confirmed by mass spectrometry. Our results indicate the feasibility of using these strategies to produce biologically active fulllength PPAR-in E. coli BL21 (DE3).
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Human peroxisome proliferator-activated receptors (PPARs), including , /, and , belong to the nuclear hormone receptor superfamily of ligand-activated transcription factors, and as a group cooperatively regulate cellular various metabolism pathways.
1) PPAR-, the best-studied member of the family, plays essential roles in controlling intracellular process, including modulation of glucose and lipid metabolism, adipocyte differentiation, and the inflammatory response, and has been established as the molecular target for treatment of type-2 diabetes, inflammation, obesity, and cancer. [2] [3] [4] [5] Antidiabetic thiazolidinediones (TZDs), such as rosiglitazone, as selective activators of PPAR-, are widely used to treat type-2 diabetes by enhancing human sensitivity to insulin.
PPAR-, like other nuclear receptors, contains four functional domains: an N-terminal A/B domain containing activation function 1 (AF-1); a DNA-binding domain (DBD) that interacts specifically with peroxisome proliferator response elements (PPREs), usually 5 0 -AACTAGGNCAAAGGTCA-3 0 in the promoter region of the target gene; a ligand binding domain (LBD) responsible for ligand specificity; and a C-terminal E/F domain that contains activation function 2 (AF-2) is critical for both ligand binding and recruiting cofactors to activate gene transcription effectively. Likewise, PPAR-functions as heterodimers with retinoid receptors (RXRs) to modulate the transcriptional activity of the target gene in response to diverse natural or synthetic ligands. [6] [7] [8] [9] [10] Several studies on truncated LBD or DBD segments have greatly enhanced our understanding of how PPAR-ligands regulate target gene expression. [8] [9] [10] [11] [12] [13] However, there is little information available on how multiple domains cooperatively impart complex physiological and pharmacological properties. Increasing evidence indicates the differences between the fulllength receptor and the isolated domain both in conformation upon binding ligand and in binding affinity for the coactivator. 14, 15) Remarkably, it has been found that ligand binding by PPAR-is regulated by intramolecular communication between its N-terminal A/B domain and LBD, 16) and that the domain-domain interaction between LBD and DBD can severely impact DNA binding by heterodimer. 17) Therefore, to investigate in detail molecular the interactions, and the relation between structure and function and more y To whom correspondence should be addressed. Tel: +86-23-66868777; Fax: +86-23-68485983; E-mail: yuyu3519@163.com Abbreviations: DBD, DNA-binding domain; DTT, dithiothreitol; EDTA, ethylenediaminetetraacetic acid; EMSA, electrophoretic mobility shift assay; GSH, reduced glutathione; GSSG, oxidized glutathione; IMAC, immobilized metal-ion affinity chromatography; IPTG, isopropyl--Dthiogalactopyranoside; LB, Luria Broth; LBD, ligand binding domain; PBS, phosphate buffered saline; PPAR-, human peroxisome proliferatoractivated receptor-; PMSF, phenylmethanesulfonyl fluoride; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; SEC, size exclusion chromatography; TB, Terrific Broth complex physiological and pharmacological properties, it is preferable to employ full-length PPAR-. Unfortunately, large quantities of physiologically active protein could not be obtained from native sources. It is essential to discover how to achieve physiologically active fulllength PPAR-for further structural and functional research. In this study, we established a systematic strategy to produce large quantities of biologically active full-length human PPAR-in E. coli BL21 (DE3).
Materials and Methods
Materials. pReceiver-B01-PPAR-plasmid was from FulenGen (Guangzhou, China). Anti-His 6 tag mouse monoclonal antibody, horseradish peroxidase-conjugated goat anti-mouse IgG, low molecular protein markers, and E. coli BL21 (DE3) were from Tiangen (Beijing, China). Tryptone, yeast extract, DNAse, RNAse, and HisLink protein purification resin were from Promega (Madison, WI). All the reagents for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and other chemicals, unless otherwise stated, were from Sigma (St. Louis, MO). [
3 H]-Rosiglitazone was from American Radiolabeled Chemicals (St. Louis, MO). The water used in the experimental work was ultrapure and was from Millipore (Bedford, MA).
Express His 6 -tagged full-length PPAR-. The open reading frame cDNA encoding amino acids 1-477 of full-length human PPAR-(GenBank accession no. NM-138712) was cloned into bacterial expression plasmid pReceiver-B01. E. coli BL21 (DE3) cells transformed with the resulting pReceiver-B01-PPAR-were allowed to grow in Luria Broth (LB) at 37 C to OD 600 of 0.4-0.6 (typically 3 h) and induced with 0.8 mM isopropyl--D-thiogalactopyranoside (IPTG). Cells were harvested by centrifugation (10;000 Â g for 10 min at 4 C), washed with ice-cold phosphate buffered saline (PBS), and stored at À80 C.
Prepare inclusion bodies. A frozen cell pellet was thawed and resuspended in 20 ml of sonic buffer (10 mM Tris pH 7.5, 100 mM NaH 2 PO 4 , 0.5 mg/ml of lysozyme, 10 mg/ml of DNAse, 10 mg/ml of RNase, and 1 mM phenylmethanesulfonyl fluoride, PMSF) per g of wet cells. Sonication was carried out on ice until the cells were completely lysed. After centrifugation at 18;000 Â g for 10 min at 4 C, the supernatant and pellet were analyzed by SDS-PAGE. We noted that almost all of the recombinant protein produced in E. coli BL21 (DE3) accumulated intracellularly in insoluble and inactive aggregates as inclusion bodies in the pellet. The inclusion bodies were washed to release contaminating and other unwanted materials using a modified procedure. 18) In brief, the collected pellet was thoroughly resuspended in 10 ml of ice-cold PBS containing 2 M urea, 0.5 mM ethylenediaminetetraacetic acid (EDTA), and 10 mM dithiothreitol (DTT) per g of starting wet cell product. The suspension was subjected to sonication on ice, followed by centrifugation at 18;000 Â g for 10 min at 4 C. The whole process was repeated 2 more times. After the third wash, the pellet was again resuspended in 5 ml of PBS containing 0.5 mM EDTA and 10 mM DTT, sonicated, and centrifuged at 18;000 Â g for 10 min at 4 C. The second wash step was repeated twice. The inclusion bodies were pelleted and stored at À80 C until use.
Purification of inclusion bodies by IMAC and SEC. The washed inclusion bodies were dissolved in lysis buffer (10 mM Tris pH 7.5, 100 mM NaH 2 PO 4 , 6 M urea and 1 mM PMSF) by sonication on ice. The resulting lysate was centrifuged at 18;000 Â g for 30 min at 4 C and filtrated through a 0.22-mm filter membrane. The proteins were purified by Ni 2þ -affinity column (Promega, Madison, WI) following the manufacturer's instructions, and then further isolated with a Sephacryl S-300 16/60 gel column (GE Healthcare, Little Chalfont, UK) attached to an Ä KTA Explorer (Amersham Pharmacia Biotech, Uppsala, Sweden). The column was run at 0.5 ml/min. The elution profile was monitored by measuring the absorbance of the eluant at 280 nm using a UV detector at all chromatography steps. Fractions containing PPARwere collected and stored at À80 C.
Refolding of the denatured full-length PPAR-. Two-step purified denatured protein was refolded by the gradual dilution dialysis method using a simplified refolding set-up ( Fig. 1 ) designed by us following a reported strategy. 19) Reservoirs A (1,000 ml) and B (1,000 ml) were used to load unfolding buffer (10 mM Tris pH 7.5, 100 mM NaH 2 PO 4 , 6 M urea, 0.4 M arginine, 25 mM Zn(OAc) 2 , 1 mM PMSF, 3 mM reduced glutathione (GSH), and 1 mM oxidized glutathione (GSSG), and refolding buffer that had the same composition as the unfolding buffer, but with 1 M urea, respectively. To enable thorough stirring, two magnets were placed into a dialysis sack and reservoir A, respectively. Ten ml starting protein materials at a final concentration of about 2 mg/ml were prepared with the unfolding buffer. Prior to the refolding experiment, 10 ml of unfolding buffer was transferred to the dialysis sack, and reservoir A was loaded with 900 ml of the unfolding buffer. When the starting protein materials were introduced into the dialysis sack at 0.02 ml/min (injection time, 500 min) from the beginning, the refolding buffer in reservoir B was pumped simultaneously into reservoir A at 2.5 ml/min under continuous stirring over the next 3,000 min. At the same time, the mixed solution in reservoir A was allowed to pump out at 2.5 ml/min. Then direct dialysis against the refolding buffer was carried out for another 1,200 min. The buffer was changed several times during dialysis. Experimental parameters similar to reference 19 were set. After the process of refolding was complete, insoluble materials were removed by centrifugation at 20;000 Â g for 30 min at 4 C. The protein concentration was measured before and after refolding to determine the refolding yield. The supernatant was concentrated up to about 3 mg/ml with Vivaspin20 (molecular weight cut-off, 10 kDa) (Sartorius, Goettingen, Germany), and further purified by SEC under non-denaturing conditions to remove aggregations and other impurity. The gel column was precalibrated using the following high-and low-molecular weight protein standards from gel filtration calibration kits (GE Healthcare): ferritin (440 kDa), aldolase (158 kDa), albumin (67 kDa), ovalbumin (43 kDa), and ribonuclease A (13.7 kDa). Blue dextran 2000 was used to determine the column void volume. The column was eluted with PBS with containing 1 mM PMSF at 0.5 ml/min. Fractions containing PPAR-were collected and stored in aliquots at À80 C.
Determination of protein concentration. The method of Bradford was used to determine the protein concentration, with bovine serum albumin as standard. 20) Electrophoresis and Western blot analysis. Polyacrylamide gel electrophoresis was carried out using 12% gels under denaturing and non-denaturing conditions. 21) Resolved protein was blotted onto nitrocellulose membrane by the Bio-Rad transfer system (Bio-Rad, Hercules, CA). The transferred membrane was blocked and incubated with anti-His 6 tag mouse monoclonal antibody and horseradish peroxidase-conjugated goat anti-mouse IgG. 3,3 0 -diaminobenzidine was used as a chemiluminescent substrate to detect immunoreactive bands.
Assay ligand binding. To test the ligand binding activity of the refolded PPAR-, the dissociation constant (K d ) was determined by a Reservoirs A (1,000 ml) and B (1,000 ml) were used to load unfolding buffer and refolding buffer respectively, and pumps were employed to pump in or out of buffer and sample.
novel SEC-HPLC method instead of radio-ligand receptor binding assay. Rosiglitazone, a high affinity PPAR-ligand, and GW9662, an irreversible PPAR-competitive antagonist, were selected for ligand saturation binding assay. Dimethylsulfoxide was used to dissolve rosiglitazone and GW9662. PBS was prepared daily, degassed by sonication, and used as ligand binding buffer and as the chromatographic mobile phase. The column temperature was 8 C. The selectivity, linearity, precision, accuracy, and recovery yield were investigated to validate the SEC-HPLC method by analysis of quality control samples. Values were obtained in three independent experiments performed in duplicate. For ligand saturation binding, 400 mg of refolded PPAR-protein was mixed in PBS with rosiglitazone in the presence or the absence of an 80-fold excess of GW9662 to determine non-specific binding or total binding, respectively. Specific binding was calculated as the difference between total binding and nonspecific binding. All components were added simultaneously to a final volume of 1 ml, and were incubated at 4 C. After incubation, 20 ml of reaction solution was loaded onto an Agilent Zorbax Bio Series GF-250 gel analytical column (4:6 mm Â 250 mm) previously equilibrated with PBS. The free (or unbound) rosiglitazone was separated from the bound rosiglitazone and other materials by elution at 0.5 ml/min, and was quantified by measuring the absorbance of rosiglitazone at 247 nm with an Agilent HPLC 1100 series VWD detector on line. At the same time, the value of K d was determined by radio-ligand receptor binding assay.
8)
Electrophoretic mobility shift assay. To determine DNA binding ability of the refolded PPAR-, electrophoretic mobility shift assays (EMSA) were performed as described previously. 17, 22) The fluorescent label, Cy5, was covalently linked to the 5-end of the oligonucleotide (5 0 -GCAAACTAGGTCAAAGGTCAG-3 0 ). Duplex DNA was prepared by hybridization of a fluorescently labeled strand and an unlabeled complementary oligonucleotide (5 0 -CTGACCTTTGACC-TAGTTTGC-3 0 ). RXR protein used for EMSA was produced in our laboratory. Binding reactions were carried out at room temperature for 30 min using EMSA/Gel Shift kits with poly(dI-dC) (Beyotime, Guangzhou, China). The samples were electrophoresed on 4% nondenaturing PAGE in 0.5 M TBE at 130 V. The gel was scanned using a two-color infrared imaging system from LI-COR (Lincoln, NE).
Digestion of full-length PPAR-in-gel. The protein bands corresponding to a positive signal on Western blot were recovered washed twice with ultrapure water, and digested in 40 mM NH 4 HCO 3 pH 8.0, 10% acetonitrile, and 20 mg/ml of trypsin overnight at 37 C. The peptides were extracted using 50 ml of 5% trifluoroacetic acid and 50% acetonitrile.
Identification of full-length PPAR-by Ion Trap MS. Identification of recombinant protein was performed with an HPLC-Chip/Ion Trap Mass spectrometry system from Agilent (Santa Clara, CA). The peptide mixtures from in-gel digestion were loaded onto an enrichment column (Zorbax 300SB-C18, 75 mm Â 43 mm) on a chip, where the peptides were trapped. The chromatographic run was performed at 4 ml/min with an aqueous phase containing 0.1% formic acid to remove salt and other water-soluble contaminants. The trapped peptides were eluted with a water/acetonitrile gradient at 0.3 ml/min. The total run time was 25 min. The eluant entered the ion trap mass spectrometer directly and the molecular mass of the ion fragments was determined. The spectrum was obtained with scanning from 300 to 1,600 m=z, while ion fragments in spectrum provided amino acid sequence information. Two different data analysis paths were employed for protein identification. One path used Agilent Spectrum Mill MS Proteomics Workbench to search against the International Protein Index (IPI) database. The other path used the Mascot generic format to search against Swiss-Prot, NCBInr, and MSDB databases by MASCOT search engine.
Results and Discussion

Expression of His 6 -tagged full-length PPAR-
The open reading frame of PPAR-cDNA in pReceiver-B01-PPAR-recombinant plasmid was sequenced and confirmed to be consistent with GenBank.
PPAR-was successfully expressed in E. coli BL21 (DE3). The apparent molecular weight of the expressed protein was estimated to be about 55 kDa, in agreement with the theoretical molecular weight deduced from the amino acid sequence of full-length PPAR- (Fig. 2A) . The ultimate aim of bacterial expression is the realization of soluble expression or high yield. Lowering the temperature or a rich medium such as Terrific Broth (TB) has been shown to facilitate proper folding of the expressing protein, and to inhibit the formation of inclusion bodies. 23) Unfortunately, using different strains (E. coli BL21 (DE3) or DH5) and variable growth conditions, such as 16 C, culture medium (TB or LB), and IPTG concentration, PPAR-was expressed as inclusion bodies (data not shown). Therefore, the methodology focused mainly on optimizing cell growth conditions to achieve high yield at 37 C. The optimal medium was rich TB, ensuring stable pH, better cell growth, and 4-fold higher cell yield (12 g/l) as compared to less rich LB (3 g/l). After induction with 0.8 mM IPTG for 3 h, the amount of protein reached the maximum. Before disruption, the cells were enzymatically lysed with lysozyme, DNases, and RNase. Successive washes with PBS containing urea were done to remove contaminants and other unwanted materials from the inclusion bodies. The washed inclusion bodies were solubilized in denaturing buffer with 6 M urea, yielding 280 mg of inclusion body protein of more than 65% purity per liter of TB culture. These results suggest that a high yield of recombinant protein was achieved by optimizing a few basic parameters, including medium condition, induction time, and IPTG concentration.
Purification of full-length PPAR-by IMAC and SEC
The recombinant protein tagged with His 6 was readily purified with Ni 2þ affinity resins under denaturing A B A, Full-length PPAR-expression under optimum conditions. lane M, protein molecular weight markers; lanes 1-2, pellet from whole cell lysates after induction with 0.8 mM IPTG for 3 h; lane 3, whole cell lysates before induction; lane 4, lysates from E. coli BL21 with empty vector. B, Purification of denatured PPAR-by Ni 2þ affinity column previously equilibrated with buffer A (10 mM Tris pH 7.5, 100 mM NaH 2 PO 4 , 300 mM NaCl, and 6 M urea) under denaturing conditions. lane 1, partially purified PPAR-from inclusion bodies after washes with 2 M urea, 0.5 mM EDTA, and 10 mM DTT; lane 2, flow-through fractions; lanes 3-4, 5-6, 7-9, and 10-11, wash-step fractions with buffer A containing 25, 50, 75, and 100 mM imidazole respectively; lanes 12-13, 14-15, elution-step fractions with buffer A containing 500 and 1,000 mM imidazole respectively.
conditions. NaCl (300 mM) was added to decrease nonspecific binding and prevent the lysozyme from binding to the resins, according to the manufacturer's instructions for the use of the product. Since purification of His 6 -tagged recombinant protein is imidazoledependent, increasing the amount of imidazole in the wash buffer can dramatically improve the purity of the recovered protein. To achieve high purity and good recovery, a stepwise gradient was used to wash the column. Impurities were removed between 25-50 mM imidazole (Fig. 2B, lanes 3-6) . Large quantities of the desired protein started to elute in a range 500 to 1,000 mM imidazole (Fig. 2B, lanes 12-15) . Approximately 15% of the target protein was lost in the flowthrough and in the wash-step fractions, as judged by SDS-PAGE analysis. This was probably because that the N-terminal histidine tag was buried inside the PPARpolypeptide, so that the target protein could not bind to the Ni 2þ affinity resins, or bound to the Ni 2þ affinity resins with low affinity. To remove possible His 6 -tagged fragments, imidazole and other impurity proteins, the IMAC-purified protein was applied to a Sephacryl S-300 16/60 gel column under denaturing conditions. The eluted fractions were monitored at 280 nm and further analyzed by SDS-PAGE. The addition of 1 M NaCl prevented binding of the proteins to the matrix and possible aggregation of proteins on column. To optimize the purification conditions, the same protein was used in all tests. We found that when the sample volume was constant, the effect of the flow rate on resolution was more notable than sample loading was (data not shown). To strike a balance between experimental time and resolution, a 0.5 ml/min flow rate was used. The elution profile showed three peaks, of which the peak containing pure PPAR-was judged by SDS-PAGE (Fig. 3) , suggesting that a large amount of PPAR-were eluted in peak I. Following IMAC and SEC purification, recombinant PPAR-176 mg of over 90% purity per liter of TB medium was obtained.
Refolding of full-length human PPAR-
The main cause of low yields of properly refolded proteins is non-specific aggregations derived from the interaction of hydrophobic cores between proteins during the refolding process. Prevention of protein aggregations had been found to be an important determinant of successful protein refolding. 24) Our initial attempts to refold the inactive PPAR-into biologically active protein using conventional dialysis or dilution to remove the denaturant directly failed. Hence a simple and feasible refolding set-up capable of gradual buffer exchange and continuous protein feeding was designed to carry out protein refolding. The aim of gradual buffer exchange was gradual removal of urea from the denatured protein inside the dialysis sack. This was achieved by using two separate pumps to exchange the unfolding buffer in reservoir A with refolding buffer towards the desired concentration of refolding buffer over a given period. The kinetic theory of refolding suggests that a low starting level of unfolded protein (10-50 mg/ml) can inhibit aggregation. [24] [25] [26] But such a low concentration increases the buffer volume dramatically and the difficulty of recovering correctly refolded proteins. A high yield of properly refolded proteins can be achieved by continuous protein feeding into the dialysis sack. 19) Hence another pump was employed to add protein automatically and control the rate of continuous feeding to inhibit aggregation. In addition, an effective buffer especially facilitates inhibition of protein aggregation. To optimize the buffer, several parameters of the buffer were assessed to determine their effects on the refolding yield. A pH value of 7.5, close to the physiological condition, was selected to ensure the stability of refolding protein. Since PPAR-has a theoretical pI of 6.19, the protein becomes negatively charged at higher pH. The increase in electrostatic repulsion between molecules can reduce protein aggregation. 27, 28) Since PPAR-contains two zinc finger domains that can coordinate zinc ions to stabilize their folds, the effect of Zn 2þ on the refolding yield was initially investigated using refolding buffer in the absence or presence of 25 mM Zn(OAc) 2 .
29) The refolding yield was improved markedly (Fig. 4A) , suggesting that Zn 2þ is required for conformational development of Pooled fractions from IMAC were loaded onto s Sephacryl S-300 16/60 gel column equilibrated with 10 mM Tris pH 7.5, 100 mM NaH 2 PO 4 , 1M NaCl, and 6 M urea, and eluted at 0.5 ml/min. Fractions (4 ml) were collected. Inset shows a 12% SDS-PAGE of the materials in the peak fractions. lane M, protein molecular weight markers; lane 1, peak I; lane 2, peak II; lane 3, peak III.
A B the two zinc finger motifs in DBD of the full length PPAR-. 26) Hence all the buffers, unless indicated otherwise, contained 25 mM Zn 2þ . The effect of different molar ratios GSH:GSSG on PPAR-refolding was investigated in detail. The refolding yield was significantly enhanced as the molar ratio GSH:GSSG increased from 1:1 to 3:1 (Fig. 4A) , but when the ratio exceeded 3:1, the refolding yield fell markedly (Fig. 4A ). This is explained by the fact that PPAR-refolding is Zn 2þ -dependent. A high concentration of GSH in the buffer decreases the concentration of free Zn 2þ and may competitively remove the bound Zn 2þ in the zinc finger motifs of PPAR-due to binding of Zn 2þ with its thiol group. This did not facilitate the development of the two zinc finger motifs in the DBD of PPAR-, leading to a reduction in the refolding yield, and thus optimal ratio of GSH to GSSG was 3:1 (Fig. 4A, line 4) . Compared with the denatured protein, the protein after refolding appeared as a narrow band as judged by non-denaturing gels (Fig. 4B, lanes 1-2) , demonstrating that PPARafter refolding probably adopted a homogeneous conformation.
SEC separates proteins on the basis of the effective size of the sample molecule of a given conformational state. Batas et al. 30) reported that denatured protein has a much larger Stokes radius and a smaller retention volume than it does in its native state. So SEC was used to determine whether the protein after refolding had converted its natural state according to the change in retention volume or retention time. The elution profile of the protein after refolding was as shown as Fig. 5A . The peak eluted within the void volume (Vo), demonstrating the presence of PPAR-aggregations. In comparison with the denatured protein (Fig. 3) , the retention volume of the PPAR-after refolding was increased about 35 ml, demonstrating that the Stokes radius of the PPAR-became smaller after refolding. This implies that the refolded PPAR-was probably refolded to its native conformation. When peak I (Fig. 5A ) was recovered, concentrated, and reloaded onto the column, the elution profile presented predominantly as a single peak (Fig. 5B) . Analysis by SDS-PAGE appeared as a single band (inset in Fig. 5B, lanes 1-2) , and Western blot confirmed the identity of the protein by anti-His antibody (inset in Fig. 5B, lane 3) . Furthermore, this profile remained essentially unchanged upon storage for several d, further demonstrating that PPAR-after refolding was stable. The whole refolding process lasted 3 d. A refolding yield of approximately 66% was achieved. It is remarkable that it was possible to refold the full-length PPAR-using the simplified refolding set-up and the optimized buffer. The protein isolated from peak II (Fig. 5B) A, Elution curve of the refolded PPAR-. Pooled supernatants from refolding were loaded onto the column pre-equilibrated with PBS, and eluted at 0.5 ml/min. B, Elution curve of the refolded PPAR-obtained from peak I in panel A. Pooled fractions from peak I in panel A were concentrated, reloaded onto the Sephacryl S-300 16/60 gel column, and eluted at 0.5 ml/min. Inset shows 12% SDS-PAGE and Western analysis of the refolded PPAR-obtained from peak II. The column was precalibrated with ferritin (440 kDa), aldolase (158 kDa), nalbumin (67 kDa), ovalbumin (43 kDa), and ribonuclease A (13.7 kDa). Vo is the column void volume calibrated with blue dextran.
Analysis of the functional activity of the refolded PPAR-
To provide adequate proof of correct folding of the refolded PPAR-, its ability to bind rosiglitazone was analyzed in vitro by a novel SEC-HPLC method. A typical SEC-HPLC chromatogram is shown in Fig. 6A , and the resulting system offered good resolution. No significant interfering peaks at or near the retention times of the samples were observed, suggesting that the selectivity of the chromatographic conditions was good. Remarkably, the free rosiglitazone was well separated from the bound rosiglitazone and presented a single peak. Thus the amount of free rosiglitazone was determined readily according to the peak area. Then A, Representative SEC-HPLC chromatogram obtained from directly mixed samples. ‹ refolded PPAR-, › GW9662, fi rosiglitazone. B, The refolded PPAR-was incubated with increasing concentrations of rosiglitazone in the absence (total binding, triangles) or the presence (nonspecific binding, squares) of an 80-fold excess of GW9662 at 4 C. The free rosiglitazone eluted from the GF-250 gel column (4:6 mm Â 25 mm) was quantified with HPLC by measuring the absorbance at 247 nm. Specific binding of rosiglitazone to PPAR-was calculated as the difference between total binding and nonspecific binding, and is indicated (circles). C, Scatchard analysis. Specific binding in B was transformed by Scatchard analysis, and linear regression yielded a K d of 250 AE 6 nM. Each point was obtained in three independent experiments each performed in duplicate.
the amount of bound rosiglitazone was calculated as the difference between the total amount of added rosiglitazone and the amount of unbound rosiglitazone. A typical equation of the standard curves of the peak area (A) to rosiglitazone concentration (C) is A ¼ 18:12 Â C À 10:32 (r ¼ 0:9991) with a linear range from 1 to 50 mM. The method yielded the limits of quantification, 7 ng (20 ml). The intra-and inter-day R.S.D was below 3.0%, the accuracy ranged from 97.8% to 100.6%, and a recovery yield of 94.1-97.7% was achieved. These results indicate that the newly established SEC-HPLC method used in this study was accurate and precise for the determination of rosiglitazone. The specific and saturable rosiglitazone binding to the refolded PPARin the absence or the presence of agonist GW9662 is shown in Fig. 6B . The specific binding of rosiglitazone (Fig. 6B) was transformed by Scatchard analysis to give a K d of 250 AE 6 nM (Fig. 6C) . Using radio-ligand receptor binding assay, K d value of 107 AE 6 nM, similar to the literature value (93 AE 7 nM) 31) was determined. These results indicate that the refolded PPAR-bound rosiglitazone with high affinity, and further confirm that the refolded PPAR-was refolded to an active conformation. The most likely cause of a K d value determined by SEC-HPLC method weaker than the literature value is that the sensitivity of the radio-ligand receptor binding assay was higher than that of the SEC-HPLC method. However, the SEC-HPLC method was simple and effective, and it overcame the disadvantage of environmental contamination and toxicity caused by radio-ligand.
In addition, the DNA binding activity of the refolded PPAR-was investigated by EMSA, in which the refolded PPAR-/RXR heterodimer bound preferentially to a double-stranded PPRE (Fig. 7, lane 1) , suggesting that the refolded PPAR-retained its biological function and that the N-terminal His 6 tag did not prevent correct folding or interfere with DNA binding activity. A light refolded PPAR-band was noted (Fig. 7, lane 4) . This is explained by the fact that PPARcan function independently, in the absence of a heteropartner, and can bind PPRE residing in the target genes to stimulate their expression. Purified tryptic fragments of PPAR-were analyzed by ion trap mass spectrometry. A, Amino acid sequence of the full-length of PPAR-and distinct matches are underlined with over 50% sequence coverage. B and C, MS of peptide segments of LLAEISSDIDQLNPESADLR and DG VLISEGQGFMTR randomly selected from 33 distinct matches respectively.
Identification of the full length PPARTo confirm the integrity of the refolded PPAR-, definitive information on the recombinant protein structure was achieved by use of Agilent HPLC-chip/ Mass Spectrometry Protein Identification Solution. The minimal gel piece corresponding to the most intense band of the protein of 55 kDa was sliced, destained, and digested with trypsin in the gel. The tryptic fragments of PPAR-purified by HPLC-Chip were analyzed by Ion Trap Mass spectrometry, which produced 33 distinct matches with the corresponding to full-length PPARaccording to a searching against the IPI database by the use of Spectrum Mill MS Proteomics Workbench. Furthermore, these distinct matches corresponded to different regions that spanned the whole of the PPARpolypeptide, with over 50% sequence coverage (Fig. 8A) . The mass spectra (MS) of the peptide segments of LLAEISS DIDQLNPESADLR and DGVLISEGQGFMTR randomly selected from 33 positive matches are shown in Fig. 8B and C, respectively. Based on m=z estimation, the MS/MS spectra were further confirmed by searching against the Swiss-Prot, NCBInr, and MSDB databases using the Mascot engine. These results confirm the identification of the recombinant protein as full-length human PPAR-.
Conclusions
In summary, we developed a systematic strategy for producing large quantities of recombinant full-length human PPAR-protein in E. coli BL21 (DE3). The protein could be refolded properly to active conformation for retention of biological function, providing a source of starting materials in amounts sufficient for structural and functional research. Due to structural similarities between the family members of PPARs, this protocol might be useful for other receptors.
